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Background: Fall incidents represent an increasing public health problem in aging societies worldwide. A major
risk factor for falls is the use of fall-risk increasing drugs. The primary aim of the study is to compare the effect of a
structured medication assessment including the withdrawal of fall-risk increasing drugs on the number of new falls
versus ‘care as usual’ in older adults presenting at the Emergency Department after a fall.
Methods/Design: A prospective, multi-center, randomized controlled trial will be conducted in hospitals in the
Netherlands. Persons aged ≥65 years who visit the Emergency Department due to a fall are invited to participate in this
trial. All patients receive a full geriatric assessment at the research outpatient clinic. Patients are randomized between a
structured medication assessment including withdrawal of fall-risk increasing drugs and ‘care as usual’. A 3-monthly falls
calendar is used for assessing the number of falls, fallers and associated injuries over a one-year follow-up period.
Measurements will be at three, six, nine, and twelve months and include functional outcome, healthcare consumption,
socio-demographic characteristics, and clinical information. After twelve months a second visit to the research
outpatient clinic will be performed, and adherence to the new medication regimen in the intervention group will be
measured. The primary outcome will be the incidence of new falls. Secondary outcome measurements are possible
health effects of medication withdrawal, health-related quality of life (Short Form-12 and EuroQol-5D), costs, and cost-
effectiveness of the intervention. Data will be analyzed using an intention-to-treat analysis.
Discussion: The successful completion of this trial will provide evidence on the effectiveness of withdrawal of fall-
risk increasing drugs in older patients as a method for falls reduction.
Trial Registration: The trial is registered in the Netherlands Trial Register (NTR1593)
Background
Falls constitute one of the most common and serious
public health problems in older populations. Fall inci-
dents are associated with considerable morbidity and
mortality [1-3]. Even a low energetic trauma, such as an
unintended fall, can lead to major injuries in older adults
with long-term consequences [4,5]. The incidence of falls
and the severity of fall-related complications rises steeply
beyond the age of 65 years [1,2,4-6]. Approximately
72,000 older adults visit an Emergency Department in
the Netherlands each year due to a fall. Over 30,000 are
hospitalized, and nearly 1,600 elderly die due to a fall per
year [7,8]. The large burden of fall-related healthcare
consumption is leading to high healthcare costs in
western societies [5,9,10]. Over the past decades several
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risk factors for falls have been identified. Major risk
factors include one or more previous falls, mobility
impairments, high age, and the use of fall-risk increasing
drugs [11,12]. The majority (73%) of older persons use
one or more drugs [13]. In 2008, nearly half of all drug
prescriptions in the Netherlands were delivered to
persons aged 65 years and older who constituted only
15% of the Dutch population in that year [14]. Adverse
Drug Reactions are frequently seen in older adults [15].
A meta-analysis of observational studies showed an
increased fall risk with certain drug groups, i.e., psycho-
tropic [16] and cardiovascular drugs [17]. Approximately
three-quarters of the community dwelling elderly used at
least one prescribed drug, and about a third used at least
one fall-risk increasing drug [13].
There is evidence that withdrawal, reduction, or substi-
tution of fall-risk increasing drugs can reduce fall risk in
older adults. Only one small, randomized controlled trial
on drug withdrawal has been performed [18]. Campbell
et al. found that withdrawal of psychotropic medication
significantly reduced the risk of falling, but permanent
withdrawal proved very difficult to achieve. Therefore the
authors made recommendations for a larger randomized
controlled trial (RCT) to study the single effect of drugs
assessment and drugs modification on fall risk. A recent
prospective cohort study with a two-month follow-up per-
iod showed that the withdrawal of fall-risk increasing
drugs was associated with a reduction in falls [19].
Furthermore, an increased susceptibility to certain
adverse drug reactions may partly be due to genetic poly-
morphisms that alter responses of individual persons to
various drugs [13]. A possible cause might be the path-
way of hepatic drug metabolization by the cytochrome
P-450 family of biotransformation enzymes [20]. Conse-
quently, poor, extensive and ultra-rapid metabolizers for
certain cytochrome pathways and membrane bound
transporters can be distinguished [21], which influence
the pharmacodynamics and pharmacokinetics. The
majority of fall-risk increasing drugs are metabolized by a
small number of enzymes, the major ones being CYP450
2D6, 2C9, 2C19 and 3A4/5 [22]. Due to polypharmacy
among older adults, the risk of a CYP 450 interaction
increases.
A systematic fall-related drugs assessment combined
with medication changes and a one-year follow-up assess-
ment among older fallers may contribute to a reduction in
the incidence of new falls and related consequences [19].
At this moment a structured medication assessments are
not part of standard care of older fallers presenting at the
Emergency Department. In the Netherlands, the current
care of fall-related injuries consists of treatment of the
injuries of the fall. However, before a systemic fall-related
medication assessment can be incorporated in the routine
work-up of older persons presenting with a fall, further
evidence is required. The aim of this randomized con-
trolled trial is to compare the effect of withdrawal of fall-
risk increasing drugs versus ‘care as usual’ on future falls.
The primary outcome of this study is be the number of
new falls and fallers. Secondary outcome measurements
are possible health effects of medication withdrawal,
health-related quality of life, costs, and cost-effectiveness
of the intervention.
Methods/Design
The study is designed as a multicenter RCT with a one-
year follow-up period in the Netherlands. The Medical
Ethics review board of the Erasmus MC, University Medi-
cal Center, approved the study protocol. The study started
in October 2008. The flow chart is shown in Figure 1.
Study population
Patients aged 65 years and over, who visit the Emergency
Department of a participating hospital due to a fall, are
eligible for inclusion. A fall is defined as coming to rest
unintentionally on the ground or a lower level with or
without losing consciousness, but not induced by acute
medical conditions, e.g., stroke, or exogenous factors
such as a traffic accident [23].
Patients meeting the following inclusion criteria are
eligible for enrollment:
1. Aged 65 years or older (no upper age limit)
2. Attended the Emergency Department due to a fall
incident
3. Taking one or more fall-risk increasing drugs for at
least two weeks prior to the fall
4. Mini-Mental State Examination score of 21/30 points
or over
5. Able to walk independently
6. Community dwelling
7. Provision of informed consent by patient
If any of the following criteria applies, patients will be
excluded:
1. Patient participation in another trial
2. Fall not meeting criteria of specified definition
3. Likely problems, in the judgment of the investigators,
with maintaining follow-up (e.g., patients with no fixed
address)
4. Not willing to complete the research protocol (such
as attending at a follow-up visit)
Procedure
All persons visiting the Emergency Department due to a
fall receive care as usual for their injuries. Within two
weeks following the Emergency Department attendance,
patients are contacted by telephone with information
about the study. All eligible study participants will
receive written information about the study and all
interested patients will receive an appointment for the
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research outpatient clinic. The visits to the outpatient
clinic take place within two months after Emergency
Department attendance. If the patient meets all eligibil-
ity criteria and no exclusion criteria are present at the
research outpatient clinic, the patient will be asked to
sign the Informed Consent Form before the study pro-
cedures take place. Patients who do not meet the inclu-
sion criteria will be excluded. During the outpatient
clinic visit a record is made of the falls risk profile
(FRP), falls history, health-related quality of life
(HRQoL) and physical performance are measured of all
study participants. Furthermore, a geriatric assessment
and a standardized medication assessment will take
place. Eligible patients will be randomized to one of the
treatment arms, the intervention group versus ‘care as
usual’. The aim in the intervention group will be to
reduce fall-risk increasing drugs, and in the ‘care as
usual’ group no (medication) change will be made. All
included participants receive a Falls Calendar for report-
ing falls during a one-year follow-up period as well as a
cost-evaluation form at three, six, nine and twelve
months after the first research outpatient clinic visit.
One year after the first visit, the study participants are
invited for a final visit to the research outpatient clinic
in order to reassess the FRP, falls history, HRQoL, and
physical performance. Adherence to their medication is
also evaluated. After the final visit to the outpatient
clinic a brief letter concerning the study start and com-
pletion will be sent to the patient’s General Practitioner.
Table 1 shows the schedule of events of this study.
Research outpatient clinic visit 
1. Verify in- and exclusion criteria 
2. Informed Consent 
3. Fall-risk profile, EQ-5D, SF-12 
4. Medical history and drug use 
5. Comprehensive geriatric assessment 
6. Tests - timed up-and-go 
 - 5x stand test  
- tandem stand test 
- orthostatic hypotension measurement 
7. Routine laboratory blood test & DNA analysis 
8. X-ray or ECG on indication 
Clinical investigator 
Randomization 
Total ƞ=620 patients 
Intervention Group 
ƞ=310 patients 
 
Systemic drug assessment including 
drug modification 
Control group 
ƞ=310 patients 
 
No drug change 
(care as usual) 
Follow-up (1-year): every 3 months falls-calendar and 
questionnaire for economic analysis 
Final visit 
1. General information, incl. medical history and drug use  
2. Questionnaires: Fall-risk profile, EQ-5D, SF-12 
3. Functional tests: timed up-and-go; 5x stand test; tandem 
    stand test; orthostatic hypotension 
Population 
Emergency Department attendance due to a fall in persons 
≥65 yr and the use of ≥1 fall-risk increasing drugs 
Figure 1 Flow chart.
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Randomization
Participants will be allocated to one of two treatment
arms using a web-based randomization program that will
be available 24 hours a day. Variable block randomization
will be accomplished via a trial website. Allocation will be
random. It is not possible to blind the geriatrician and
patients for the allocation of the study group.
Intervention
The single intervention will consist of a systematic
fall-related medication assessment combined with drug
withdrawal or modification, if safely possible. Fall-risk
increasing drugs, as defined in the literature [16,17,19,24],
will be stopped, reduced or substituted with potentially
safer drugs in the intervention group. A complete list of
fall-risk increasing drugs, based on current literature, is
shown in Table 2.
For each drug, the clinical investigator will assess
whether the initial indication still exists. Proposed changes
in medication will be discussed with a senior geriatrician
and the participant’s General Practitioner and with the
prescribing doctor if other than the General Practitioner.
If consensus is obtained, fall-risk increasing drugs will be
discontinued when considered redundant, reduced in dose
over a one-month period, if safely possible, or substituted
for potentially safer drugs if necessarily and available. For
each drug modification, the clinical investigator will follow
the standardized instructions of the Dutch National
Formulary [25], and a clinical pharmacologist will be avail-
able for advice when needed. A research nurse will offer
counseling and evaluate possible negative effects by weekly
telephone calls over a period of 1 month, and discuss any
problems with the clinical investigator and the geriatrician
(project leader).
Outcome measures
The primary outcome measure will be the incidence of
new falls, fallers, based on the Falls Calendar. Secondary
outcome measures will be fall-related injuries, generic
health-related HRQoL, compliance, quality adjusted life
years (QALY), genetic polymorphisms associated with
increased adverse drug reactions, and positive or nega-
tive health effects, cost, and cost-effectiveness.
Measurements
Medication use
Medication use will be assessed by registering the drug
names directly from the medication packaging. For each
drug, both prescription and over-the-counter (OTC), the
name, intake frequency, dosage, start and stop dates, and
whether the drug was prescribed before or after the fall
will be registered. The information will be verified and
compared with data retrieved from the patients’ General
Practitioner and local pharmacist.
Quality of life
The level of independency of the activities of daily living
(ADL) will be examined using the Barthel Index (ranging
from zero for full independency to 20 for full dependency)
[26]. Quality of life will be measured using the Dutch ver-
sion of the SF-12 and EQ-5D (EuroQol) questionnaire.
The EQ-5D has been designed by the Euro-HRQoL
Group to assess the experienced general quality of life in
large populations in order to provide a simple, generic
measure of health for clinical and economic appraisal [27].
The EQ-5D questionnaire covers five health domains
(mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression) and a Visual Analogue Scale (VAS) to
Table 1 Schedule of events
Screening 1st visit 3 months 6 months 9 months 12 months
Telephone call X
Information package X
Informed Consent X
Randomization X
Baseline data X
EQ-5D X X
SF-12 X X
FRP X X
Orthostatic hypotension test X X
Complications X X X X
Falls calendar X X X X
Healthcare consumption X X X X
ADL X X
Physical functioning (VAS) X X
EQ-5D, EuroQol 5-D questionnaire; SF-12, Short Form-12; FRP, Fall Risk Profile; ADL, Activities of Daily living; VAS, Visual Analogue Scale.
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record the current experienced health status. The EuroQol
(EQ-5D) is a validated and extensively used general health
questionnaire to measure quality of life [28,29]. It is
recommended for the assessment of HRQoL in trauma
patients, especially for economic assessments [30]. The
SF-12 contains 12 questions and has been designed and
validated to assess the quality of life in large population
studies [31,32]. Fall-risk will be assessed using a validated
FRP [33]. The FRP contains five questions, two measure-
ments (handgrip strength and body weight), and two inter-
acting items. Hand grip strength will be measured using a
digital strain-gauged dynamometer (Takei TKK 5401,
Takei Scientific Instruments Co, Ltd., Tokyo, Japan). Body
weight will be measured with a calibrated beam scale. For
each item points are scored and summed (range 0-30),
where zero represents a low risk of recurrent falling and
11 and over indicates a high risk of recurrent falling (2 or
more falls in the next 12 months) [33].
Physical performance
In order to assess the physical activity, three tests will be
conducted. First, the chair stand test, which is a standar-
dized test in which the participant stands up and sits
down five consecutive times. The patient is not permitted
to use the chair’s arms supports during standing up or sit-
ting down [34]. The Timed Up-and-Go test (TUG-test)
will be conducted, in which the participant has to stand
up from sitting position and walks three meters along a
line, perform a 180 degree turn and walk back to the chair
and sit down [34]. A tandem stand test will be used in
order to assess balance. The test will be performed in
standing position, in which the patient has to stand fully
independently for 10 seconds with both feet in front of
each other, and is scored as correct or failed. All three
mobility tests are conducted twice, and the best time
(where appropriate) will be used.
Orthostatic hypotension will be measured by using a
calibrated sphygmomanometer, in supine position fol-
lowed by five minutes standing straight up. The blood
pressure will be measured in supine position and after
one, two, three, four, and five minutes standing. The
blood pressure is registered in millimetres of mercury
(mmHg), heart rate in beats per minute. Orthostatic
hypotension is defined as a decrease of 20 mmHg systo-
lic or a decrease of 10 mmHg diastolic in standing posi-
tion [35].
Costs
The total direct and indirect costs of both fall-risk increas-
ing drugs withdrawal and ‘care as usual’ will be measured.
All analysis will be performed in accordance with Dutch
guidelines for economic evaluations [36]. Direct healthcare
costs include the additional costs of the systematic fall-
related drugs assessment and modification, drug con-
sumption (including the costs for substitution drugs), and
fall-related and non-fall-related healthcare consumption
during one year of follow-up (e.g. General Practitioner,
outpatient visits, and hospital admissions).
Real medical costs are calculated by multiplying the
volumes of health care use with the corresponding unit
prices. For the intervention (systematic fall-related drugs
assessment) the full cost price will be calculated and for
the other health care costs standard cost prices will be
used as published by Oostenbrink [36]. The full cost price
of patient identification at the Emergency Department and
the systematic fall-related drugs assessment will be deter-
mined based upon time measurements and employment
of personnel. Costs of medication use will be recorded in
the study, and unit costs will be determined with informa-
tion from the National Dutch Formulary [25].
Healthcare consumption, both fall and non-fall related,
and patient costs will be recorded from the Hospital
Information System for hospital care, and three-monthly
questionnaires for other healthcare and patient costs.
These will be supplemented with data on healthcare
costs of injury from previous research [9]. The number of
injuries prevented will be calculated with data recorded
Table 2 Drugs classified as fall-risk increasing drugs in the IMPROveFALL study
Category Drug type
Central nervous
system
anxiolytics/hypnotics (benzodiazepines and others); antidepressants (tricyclic antidepressants, selective serotonin reuptake
inhibitors, serotonin-norepinephrine reuptake inhibitors and monoamine oxidase inhibitors), neuroleptics (dopamine D2-
receptor agonists and serotonin dopamine receptor antagonists)
Cardiovascular Antihypertensives (diuretics, beta-adrenoceptor blockers, alpha-adrenoceptor blockers, centrally acting antihypertensives,
calcium channel blockers, angiotensin converting enzyme inhibitors and angiotensin receptor blockers); Anti-arrhythmic
drugs (Antiarrhythmics, nitrates, digoxin, vasodilators)
Anti-inflammation NSAIDs
Gastro-Intestinal Antacids (H-2 receptor antagonists)
Analgesics Opioids
Pulmonary Sympathomimetics, anti-histaminics
Diuretics Thiazide diuretics, loop diuretics
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in the study, supplemented with epidemiological data on
falls and injury risks.
Cost-effectiveness will be assessed by calculating the
incremental cost-effectiveness ratio, defined here as the
difference in average costs between medication assess-
ments including withdrawal of fall-risk increasing drugs
and ‘care as usual’ and by the difference in prevented fall-
related injury. Secondary, a cost-utility analysis will be per-
formed, i.e., as cost per Quality Adjusted Life Years
(QALY). Policy makers and health economists have pro-
posed that costs varying from €25,000 up to €75,000 per
QALY may be considered as acceptable [37,38].
The QALY combines mortality and morbidity into a sin-
gle number. The morbidity component is referred to as
HRQoL and is based on a descriptive health-state mea-
sure. Because of a long track record in health economic
analyses, the EQ-5D measure will be used for this purpose
[28]. Furthermore, the lifetime health effects (cardiovascu-
lar events such as myocardial infarction, stroke, and mor-
tality) due to possible increased cardiovascular risks (i.e.,
cardiac failure, rebound hypertension) will be calculated
with existing models for cardiovascular disease risk man-
agement. In accordance with guidelines for differential dis-
counting, effects will be discounted at a rate of 1.5% and
costs at 4% per year [39].
Full blood for DNA isolation will be drawn during the
first visit (5 mL). The blood will be stored at -80 degrees
Celsius, until DNA-isolation will take place. After DNA
isolation, polymorphisms (CYP1A2, CYP2C9, CYP2C19,
CYP2D6, CYP2E1 en CYP3A4) will be analyzed using the
TaqMan allelic discrimination assays on the ABI Prism
9700 HT sequence detection system. If needed, other poly-
morphisms will be added to the analysis.
Follow-up
Patients will be followed for one year. After the first visit
to the research outpatient clinic patients receive a Falls
Calendar [33]. During a one-year follow-up period, the
participant will be asked to record every week whether
they have experienced a fall that week. The 3-monthly
calendar sheet will be returned once per 3-months by
mail. Cost-effectiveness will be measured using a cost-
evaluation questionnaire. Participant can register the num-
ber of visits to physicians, therapists, day care centers,
hospitalizations, adaptations of the living area, and the
current living location (e.g., home or nursing home). The
cost-evaluation questionnaire will be returned with the
falls calendar at three, six, nine, and twelve months after
the first visit to the research outpatient clinic. In case no
calendar sheet or questionnaire is received, or when it is
completed incorrectly, the calendar sheet or questionnaire
will be completed by telephone.
During the last visit to the outpatient clinic, one year
after the first visit, all physical performance tests are
conducted, as well as questionnaires regarding medical
history, drug use, quality of life, and fall risk profile.
Adherence to the drug-use recommendations (complete
withdrawal, lowering of dosage, or substitution) will be
evaluated by reassessment of drug use as described
above. Information of the participants regarding medical
history and drug use will be verified by the General
Practitioner and local pharmacist.
Sample size calculation
A total number of 620 patients will be included in the
study, 310 in the control group and 310 in the interven-
tion group. Calculation of the required sample size is
based on the assumption that the annual cumulative inci-
dence of further falling is 50% without intervention [40], a
15% drop-out (including death) [11], drug withdrawal
being possible in 50% of the participants in the interven-
tion group and a 50% decrease of further falls among par-
ticipants with successful withdrawal [18]. A single-sided
test with an alpha level of 0.05 and a beta of 0.2 indicates
that 310 patients in both groups is sufficient in order to
detect a 25% decrease of respondents reporting further
falls in the intervention group.
Statistical analysis
Data will be primarily analyzed according to the intention-
to-treat principle. Patients with protocol violations will be
followed up, and data will be recorded. Data will be ana-
lyzed with and without inclusion of patients with protocol
violation. At baseline, differences in baseline characteris-
tics will be compared between the intervention and con-
trol group in order to assess comparability between the
two groups. Student’s T-test (parametric numeric data),
Mann-Whitney U-test (nonparametric numeric data) or
Chi-square test (categorical data). Data will be presented
as mean ± SD (parametric data) or medians and percen-
tiles (non-parametric data).
The hazard ratio for falling will be calculated using a
Cox-regression model. Herein, the time between the inter-
vention (i.e., drug assessment/change or not) and the first
and/or second fall will serve as the primary outcome mea-
sure. Fallers will be defined as those who will fall once or
more during the one-year follow-up. Differences in cumu-
lative incidence of falls will be analyzed using log-linear or
Poisson regression, adjusted for over dispersion because of
interdependence among the dependent variable (falls). Dif-
ferences in adverse health effects between both trial arms
will be assessed using Chi2 testing. Several subgroups will
be distinguished in order to examine whether the effect of
the intervention depends upon sex, age, race and risk of
future falls. Since healthcare costs per patient are typically
highly skewed, non-parametric techniques will be used to
derive a 95% confidence interval for the differences in dis-
tributions of the costs. In a sensitivity analysis the impact
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on cost-effectiveness of statistical uncertainty on the main
study outcomes will be determined (uni- and multi-
variable).
The association between genetic polymorphisms and
falls history will be evaluated using a multivariate logis-
tic regression analysis. A p-value of < 0.05 will be used
as threshold for statistical significance.
Ethical considerations
The study will be conducted according to the principles
of the Declaration of Helsinki (59th World Medical Asso-
ciation General Assembly, Seoul, October 2008 [41]) and
in accordance with the Medical Research Involving
Human Subjects Act (WMO). The Medical Ethics review
board of the Erasmus MC acts as central ethics commit-
tee for this trial (reference number MEC-2008-254;
NTR1593). In addition approval has been obtained from
the local Medical Ethics review boards in all participating
hospitals. An information letter regarding the patients’
participation and severe abnormal findings will be sent to
their general practitioners, unless a patient does not
agree with this. Liability insurance has been obtained,
which is in accordance with the legal requirements in the
Netherlands (Article 7 WMO and the Measure regarding
Compulsory Insurance for Clinical Research in Humans
of 23th 2003). This insurance provides cover in case of
damage to research subjects through injury or death
caused by the study.
Discussion
The strength of this study is that a single intervention,
the withdrawal of fall-risk increasing drugs, will be stu-
died versus ‘usual care’ using a randomized controlled
approach. The study results will provide valuable knowl-
edge for clinicians and healthcare policymakers on the
necessity of withdrawal of fall-risk increasing drugs in
falls prevention strategies in the older population. If pro-
ven effective and cost-effective, fall-risk increasing drugs
withdrawal in persons with a high risk of recurrent fall-
ing, might lower the risk of future falls and consequently
contribute to reductions in fall-related injuries, related
healthcare consumption, and costs. As far as we are
aware, up till now no large RCT’s have been published
reporting the effects of withdrawal, dose reduction or
substitution of fall-risk increasing drugs after a fall. The
inclusion of patients started October 2008 and is
expected to be complete by July 2011. Because of the
one-year follow-up period, presentation of data can be
expected in the second half of 2012.
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